Incidence of renal Fanconi syndrome in patients taking antiretroviral therapy including tenofovir disoproxil fumarate.

about

Incidence of renal Fanconi syndrome in patients taking antiretroviral therapy including tenofovir disoproxil fumarate.

Item

http://www.wikidata.org/entity/Q40099241

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Incidence of renal Fanconi syn ...... tenofovir disoproxil fumarate.

@en

type

Item

label

Incidence of renal Fanconi syn ...... tenofovir disoproxil fumarate.

@en

prefLabel

Incidence of renal Fanconi syn ...... tenofovir disoproxil fumarate.

@en

P1476

Incidence of renal Fanconi syn ...... tenofovir disoproxil fumarate.

@en

P2093

Eric Pf Chow

http://www.w3.org/2001/XMLSchema#string

Marcus Chen

http://www.w3.org/2001/XMLSchema#string

Rowan G Walker

http://www.w3.org/2001/XMLSchema#string

Tim Rh Read

http://www.w3.org/2001/XMLSchema#string

P2860

A new equation to estimate glomerular filtration rate

The role of drug transporters in the kidney: lessons from tenofovir

Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.

Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.

Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients

A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection.

Clinic Network Collaboration and Patient Tracing to Maximize Retention in HIV Care

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system.

Renal function with use of a tenofovir-containing initial antiretroviral regimen

P304

956462417722133

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0956462417722133

http://www.w3.org/2001/XMLSchema#string

P50

Christopher K. Fairley

Nicholas Medland

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28764611

http://www.w3.org/2001/XMLSchema#string